- Trials with a EudraCT protocol (374)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
374 result(s) found for: Primary metabolites.
Displaying page 4 of 19.
EudraCT Number: 2016-000810-31 | Sponsor Protocol Number: na | Start Date*: 2016-07-08 |
Sponsor Name:Maastricht University | ||
Full Title: Impact of L-Carnitine infusion on Lipid induced Insulin resistance | ||
Medical condition: Glucose tolerance | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006579-19 | Sponsor Protocol Number: MP-EG-002 | Start Date*: 2007-04-19 | |||||||||||
Sponsor Name:Egalet a/s | |||||||||||||
Full Title: A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the ... | |||||||||||||
Medical condition: cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019568-35 | Sponsor Protocol Number: OPTIM IMATINIB | Start Date*: 2010-06-14 |
Sponsor Name:CH VERSAILLES | ||
Full Title: A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (GliveecĀ®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemi... | ||
Medical condition: Chronic Phase Chronic myelogenous leukemia (CP CML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003529-41 | Sponsor Protocol Number: ABR58805 | Start Date*: 2017-02-22 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia | ||
Medical condition: Schizophrenia patients | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000084-41 | Sponsor Protocol Number: HGT-MLD-049 | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies Inc | |||||||||||||
Full Title: A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD) | |||||||||||||
Medical condition: Metachromatic Leukodystrophy (MLD) in late infantile patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Prematurely Ended) IT (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005059-10 | Sponsor Protocol Number: Trp-IBD | Start Date*: 2018-09-14 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores | ||
Medical condition: Inflammatory Bowel Disease (IBD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001879-37 | Sponsor Protocol Number: GB1275-1101(KEYNOTE-A36) | Start Date*: 2020-01-14 |
Sponsor Name:GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc. | ||
Full Title: A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination... | ||
Medical condition: Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinoma Phase 2: Specified metastatic solid tumors | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2008-002361-31 | Sponsor Protocol Number: GS-US-228-0101 | Start Date*: 2008-09-09 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohe... | |||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003369-16 | Sponsor Protocol Number: GWAP19030 | Start Date*: 2020-06-02 |
Sponsor Name:GW Research Ltd. | ||
Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate... | ||
Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-001766-90 | Sponsor Protocol Number: LuAA21004_311 | Start Date*: 2009-04-09 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxie... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004365-27 | Sponsor Protocol Number: EDP-305-101 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Enanta Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohep... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003106-28 | Sponsor Protocol Number: 73841937NSC2001 | Start Date*: 2019-11-26 | |||||||||||
Sponsor Name:Janssen Research & Development, LLC [...] | |||||||||||||
Full Title: A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell... | |||||||||||||
Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002442-23 | Sponsor Protocol Number: GS-US-428-4025 | Start Date*: 2017-01-09 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002939-18 | Sponsor Protocol Number: GWEP1447 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:GW Research Ltd. | |||||||||||||
Full Title: A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P ... | |||||||||||||
Medical condition: Epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001547-46 | Sponsor Protocol Number: MO28230 | Start Date*: 2012-08-22 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic ga... | ||||||||||||||||||
Medical condition: Her2 postive metastatic breast cancer and Her2 positive locally advanced or metastatic gastric cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) PT (Completed) SK (Completed) IT (Completed) DE (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001424-12 | Sponsor Protocol Number: 747-201 | Start Date*: 2009-04-21 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals | |||||||||||||
Full Title: A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis | |||||||||||||
Medical condition: Primary biliary cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) ES (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000998-39 | Sponsor Protocol Number: TIDE-13-22 | Start Date*: 2014-10-30 | |||||||||||
Sponsor Name:Helsinn Healthcare SA | |||||||||||||
Full Title: Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. el... | |||||||||||||
Medical condition: Chemotherapy Induced Diarrhea (CID) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005510-20 | Sponsor Protocol Number: C10953/1100 | Start Date*: 2013-03-07 |
Sponsor Name:Cephalon, Inc. | ||
Full Title: A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/day) in Children and Adolescents w... | ||
Medical condition: Excessive Sleepiness associated with Narcolepsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-002315-41 | Sponsor Protocol Number: RDEA806-501 | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects with Symptomatic Gout | |||||||||||||
Medical condition: Gout | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005581-37 | Sponsor Protocol Number: 5946 | Start Date*: 2012-08-06 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients | |||||||||||||
Medical condition: Cognitive function and sleep pattern in HIV-1 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
